Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Article Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies frequently take a niche approach, developing medicines that target a specific cancer type with a dedicated mechanism of action. Several promising treatments have shown significant potential—and with that comes the possibility of considerable sales. Two smaller biotech companies are seeing strong share-price momentum thanks to their leading oncology medicines. Beyond offering meaningful therapeutic potential, these drugs could help the firms move past penny-stock or otherwise unstable status toward greater stability and, potentially, long-term profitability. That said, both companies still face substantial risks, making them typical high-risk, high-reward biotech investments. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Silver Is Now a Growth AND Income Play For decades, silver paid nothing. That just changed. One tiny ETF is delivering 20% annualized distributions plus 68% share appreciation in just 5 months. Click here to learn more about this fund. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. The rally added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street implies there could be roughly 71% more upside from current levels. The primary catalyst for Iovance's share gains is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States for melanoma since 2024 and is building momentum—both in sales and in the potential for additional approvals in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in U.S. peak sales. Its real potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and could be effective against other tumor types under investigation. Iovance's outperformance this year was also supported by its Q4 2025 earnings report, issued in late February, in which the company reported smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year. Iovance is a small (~$2 billion) biotech that still trades like a penny stock, and despite the rally analysts remain cautious: about half of its roughly a dozen ratings are Hold or Sell. Risks remain high. Beyond the usual challenges for smaller biotechs, Amtagvi's personalized nature makes it costly and complex to manufacture — a constraint that could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, yet its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026, and analysts remain constructive: the consensus price target is $13.60, roughly 70% above the stock's current level even after the recent run. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva has driven the firm's revenue surge, delivering $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in additional cancer types, and ImmunityBio is actively exploring other indications. Despite the dramatic gains, IBRX remains speculative. The company reported a sizable full-year net loss of $351 million for 2025 as R&D expenses continue to climb. Analysts are somewhat more bullish on ImmunityBio than on Iovance: six of seven analysts rate the shares a Buy or equivalent.
| 
